Screening for Anti-amyloid Treatment Eligibility Using Digital Cognition and Blood-based Biomarkers

Inclusion Criteria: * Must be referred to the MoCA Clinic; including both new patients and existing patients who have been seen \>1 year ago * Present with cognitive impairment or cognitive complaints. * Must have the ability to understand the purpose and risk of the Study and provide informed consent. * Must have an identified study partner (informant/care partner), who has frequent and sufficient contact with the participant to be able to provide accurate information about the participant's cognitive and functional abilities. The study partner must be available by phone to provide information to the study staff about the participant and agrees to attend one in-person visit at the MoCA Clinic which requires partner input. The study partner should be available for the duration of the study. Exclusion Criteria: * An established diagnosis (other than AD), that is a cause for a candidate's cognitive impairment (e.g. substance abuse, cerebrovascular conditions, Lewy body dementia, fronto-temporal dementia, recent head trauma). * Blood donation (1 unit) within 1 month prior to Study screening. * Inability to comply with requirements to complete essential components of the Study (e.g. visual impairment, severe kidney disease or ongoing kidney treatment) * Patients already enrolled in any clinical trial for AD at time of Study screening * Other unspecified reasons that, in the opinion of the Principal Investigator, or MoCA Clinic and Institute, make the candidate unsuitable for enrolment.